Chilton Investment Co. LLC increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.4% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 269,367 shares of the company’s stock after acquiring an additional 25,287 shares during the period. IDEXX Laboratories makes up approximately 2.1% of Chilton Investment Co. LLC’s holdings, making the stock its 17th largest holding. Chilton Investment Co. LLC owned about 0.31% of IDEXX Laboratories worth $58,706,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Signaturefd LLC acquired a new position in shares of IDEXX Laboratories in the 1st quarter valued at approximately $105,000. Three Peaks Capital Management LLC acquired a new position in shares of IDEXX Laboratories in the 1st quarter valued at approximately $108,000. Optimum Investment Advisors acquired a new position in shares of IDEXX Laboratories in the 1st quarter valued at approximately $139,000. Cerebellum GP LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $181,000. Finally, Winthrop Advisory Group LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $206,000. 91.19% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms recently issued reports on IDXX. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $274.00 price target on the stock in a research report on Thursday, August 2nd. Credit Suisse Group upped their price target on IDEXX Laboratories from $228.00 to $231.00 and gave the company an “outperform” rating in a research report on Thursday, June 21st. Canaccord Genuity reissued a “positive” rating and set a $215.00 price target on shares of IDEXX Laboratories in a research report on Monday, May 7th. BidaskClub lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 31st. Finally, Stifel Nicolaus upped their price target on IDEXX Laboratories from $215.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, May 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. IDEXX Laboratories has a consensus rating of “Buy” and a consensus target price of $244.00.

IDXX stock opened at $253.48 on Friday. The company has a current ratio of 0.96, a quick ratio of 0.73 and a debt-to-equity ratio of -14.77. The company has a market cap of $21.79 billion, a P/E ratio of 66.24, a PEG ratio of 2.30 and a beta of 0.69. IDEXX Laboratories, Inc. has a 12-month low of $146.09 and a 12-month high of $256.22.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Wednesday, August 1st. The company reported $1.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.17 by $0.06. The business had revenue of $580.75 million for the quarter, compared to analyst estimates of $574.68 million. IDEXX Laboratories had a negative return on equity of 703.80% and a net margin of 14.50%. The business’s revenue was up 14.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.87 EPS. sell-side analysts expect that IDEXX Laboratories, Inc. will post 4.18 earnings per share for the current year.

In related news, Director Bruce L. Claflin acquired 415 shares of the stock in a transaction that occurred on Friday, August 3rd. The stock was purchased at an average cost of $242.12 per share, for a total transaction of $100,479.80. Following the purchase, the director now directly owns 1,415 shares in the company, valued at $342,599.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Michael Lane sold 5,912 shares of the company’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $243.78, for a total value of $1,441,227.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 70,129 shares of company stock worth $17,159,219. Corporate insiders own 2.56% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

See Also: NASDAQ Stock Market Explained

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.